crypto with potential 2022 People also ask

Yingsi Intelligent announced that it had received a milestone payment of $10 million from Exelixis. On December 13th, Yingsi Intelligent, a biomedical technology company, announced that based on the progress made in the clinical stage of XL309(ISM3091) project, the company had recently received the first clinical milestone payment from Exelixis, with a total amount of $10 million.Apple is reported to cooperate with Broadcom to develop AI chips, and TSMC's advanced process will welcome big orders again. On December 13, it was reported that Apple intends to invest in self-developed AI chips, jointly develop them with Broadcom, and produce them in TSMC's 3 nm process, and mass-produce them in 2026. The legal person is optimistic that after the development of Apple's self-developed AI chip is completed, the investment is expected, and TSMC's advanced process will usher in another big order. It is understood that Apple's current A-series processors for iPhone and M-series processors for Mac all adopt self-developed strategies, and are exclusively manufactured by TSMC. The legal person believes that once Apple's self-developed chips are extended to AI chips, the cooperation with TSMC will be closer. (Taiwan Province Economic Daily)This year's performance is the worst since the epidemic, and Starbucks will reduce the salary increase for its employees. An internal document shows that in view of the company's worst financial performance since the epidemic, Starbucks will reduce the salary increase for its coffee shop employees. According to different qualifications, this year's salary increase is generally between 2% and 3%, while last year's salary increase was at least 3%, and employees who have served for five years or more were at least 5%. The salary increase will take effect on December 30, and employees will see the change of payroll on January 10 or January 17.

According to people familiar with the matter, Trump's advisers and officials from his newly formed government efficiency department asked him if he could abolish the Federal Deposit Insurance Corporation (FDIC).Li Tie's family members were not present at the trial today, and the verdict in the first instance of Li Tie's case will start at 8:30 on time today. It is understood that after the trial today, it will directly enter the sentencing procedure, and the presiding judge will read the verdict and then ask the parties whether to appeal. Besides, apart from the defense lawyer, Li Tie's family did not come to the scene. (CCTV)Full-page observation of People's Daily: Accelerate the construction of world-class universities and advantageous disciplines with China characteristics.

Onlikon: Compound α-keto acid tablets are planned to be selected for the tenth batch of national centralized drug procurement. Onlikon announced on December 13, and on December 12, the company participated in the bidding for the tenth batch of national centralized drug procurement organized by the National Drug Joint Procurement Office. After the bid opening and evaluation by the Joint Procurement Office, the company plans to select this centralized drug procurement. The indication of that medicine is to prevent and treat the damage caused by metabolic disorder in protein due to chronic renal insufficiency. The drug is a national medical insurance catalogue product, with an annual sales of 218,900 yuan in 2023, accounting for 0.01% of the company's annual operating income in 2023.Japan's short-term survey index of large-scale manufacturing industry in December reported 14, with an estimated 13.Citic Jiantou Pharmaceutical's 2025 strategy: looking for new additions and integration opportunities. Citic Jiantou said that looking forward to 2025, the reform policy in the medical field has been normalized, and the most noteworthy incremental policy in the medical insurance field is to establish a diversified payment system. The medical field is about to usher in the reform of "deep water areas" such as salary system and graded diagnosis and treatment, which is in line with expectations as a whole. At the same time, the innovation of China's pharmaceutical industry has gradually stepped onto the international stage, some sub-sectors will be marginally improved, and industry integration will begin. We are optimistic about the investment opportunities in the pharmaceutical industry in 2025. It is suggested to focus on the new increase (innovation, going out to sea, marginal change) and industry integration opportunities.